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We are grateful to Dr Catalana-
Lopez for his continued comments
regarding our work.
Although we do not want to prolong
unnecessarily this correspondence, a
couple of points are worthy of note
in his response.
First, the suggestion of including
observational evidence in the meta-
analysis is flawed, and we found our-
selves in this position. As Rosenbaum
and Rubin,1 the propensity score
methods used by the authors can
only address confounding when case
mix adjustment is possible to the
extent that the prescriber’s decision
to prescribe a treatment is otherwise
ignorable. This is clearly not the
case in our situation, in which the732 The Journal of Thoracic and Cobservational studies describe a sub-
stantial latency (unmeasurable bias)
associated with the decision to pre-
scribe, which has been incorrectly in-
terpreted as a risk associated with
aprotonin.2,3 Thus, following Dr
Catalana-Lopez’s advice in this
situation would actually compound
the previous errors of interpretation
that have led us to our difficulties
with this agent.
Second, Dr Catalana-Lopez is sim-
ply incorrect when he suggests that
network meta-analyses have the
same status as observational studies.
Network meta-analyses preserve the
original randomization in trials, and
provide fully conditional estimates of
treatment effect. However, network
meta-analyses require an additional
assumption (of exchangeability; ie,
that subjects share characteristics
from the overall population and may,
thus, appear in any of the trials).
Thus, rather than fully giving up the
protection of randomization, we may
consider network meta-analyses to
be quasi-randomized estimates.
Finally, with regard to potential
conflicts of interest, they should be
declared upfront and leave the reader
to decide of their importance. These
authors take conflicts of interest seri-
ously and, as indicated by Dr
Catalana-Lopez, have declared all
possible conflicts in accordance with
required journal requirements.
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CARDIOPROTECTION BY
REMOTE PRECONDITIONING
WITH ISOFLURANE BUT NOT
PROPOFOL IN CABG
To the Editor:
We read with great interest the
article by Kottenberg and colleagues1
published online in The Journal of
Thoracic and Cardiovascular Surgery
onMarch 1, 2013. They have done a se-
ries of impressive translational works to
explore the underlying mechanisms of
cardioprotection by remote ischemic
preconditioning (RIPC) with isoflurane
or propofol in patients undergoing coro-
nary artery bypass grafting (CABG).1-3
In their fundamental study published in
Acta Anaesthesiologica Scandinavica,2
they designed 2 independent substudies
and found that isoflurane may be
more effective in the preservation of
cardioprotection by RIPC than
propofol. Then, based on 2 conse-
quently separated and independent
studies,2,3 they believed that differen-
tial activation of signal transducer
and activator of transcription 5
(STAT 5) phosphorylation may be the
contributing factor.
Nevertheless, there remains incon-
clusive information about this inter-
esting issue when looking into the
fundamental study. In that study,2 the
male proportion may be even within
the substudy (RIPC vs control with
isoflurane; RIPC vs control with pro-
pofol); however, it may be uneven be-
tween the 2 substudies (isoflurane vs
propofol, 89.7% vs 75.8%; mean dif-
ference, 14%).
Accumulating evidence from ani-
mal studies has supported gender-
specific cardioprotection by ischemic3
